# A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct05688605/  
OnCo record `nct05688605` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MRG003+HX008 in advanced solid tumours, run by Lepu Biopharma Co., Ltd., now recruiting.

## Summary

A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT05688605 by Lepu Biopharma Co., Ltd., with 18 participants planned, started 2022-06-30 and due to reach its primary completion in 2027-08. Interventions recorded: MRG003+HX008.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05688605
- Phase: 1/2
- Setting: An Open-label, Multi-center, Phase I/II Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of MRG003 in Combination With HX008 in Patients With EGFR-positive Advanced Solid Tumors
- Sponsor: Lepu Biopharma Co., Ltd.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT05688605: https://clinicaltrials.gov/study/NCT05688605

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Lepu Biopharma](https://onco.cc/companies/lepu-biopharma/)

---
JSON: https://onco.cc/api/v1/entities/nct05688605.json